New Site Describes Expertise-Based Clinical Research Services Including Consulting, Business, Trials, and Biospecimen Services
SEATTLE, April 4, 2012 /PRNewswire-iReach/ — Global BioClinical (GBC) the Seattle-based contract consulting and clinical research services company has launched a new website at www.globalbioclinical.com. The site offers expanded information on the company, services offered, partner registration, new search capabilities, and links to common professional and social networking sites.
The service descriptions function as a benchmark source of information for clients in life sciences, clinical research, and biopharmaceutical product development. “We believe that there is a niche for our expertise to improve clinical study execution and quality, and ultimately make new healthcare products more available to patients”, says Neil R. Mucci, CEO.
About – Global BioClinical
Global BioClinical (GBC) is a contract consulting and clinical research organization (CRO) with core expertise in organizational and project management, clinical trial planning and execution, and human biospecimens. GBC works with clients in the life sciences and healthcare research sector including early-stage and established medical device and biotechnology companies, pharmaceutical companies, medical centers and health systems, research and academic institutions, government agencies and sub-contractors, venture capital groups, and not-for-profit groups. GBC supports predictive, prognostic, personalized, and participatory medicine with the leading goal of moving healthcare products to the market more quickly, with less risk, and with a greater return on investment.
GBC – GLOBAL BIOCLINICAL
Expertise-Based Clinical Research Services
Consulting – Business – Trials – Biospecimens
93 S. Jackson St.
Seattle, WA 98104-2818 U.S.A.
Main: +1 888 659 1221
Linked In: www.linkedin.com/company/global-bioclinical
Media Contact: GBC Press, Global BioClinical, 1-888-659-1221, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Global BioClinical